

VIDEO - Platforms, Products, and Services: A New Lens on US Equity Risk

[Platforms, Products, and Services: A New Lens on US Equity Risk](#)



Background: We used ChatGPT to tag the top 2,000 US equities as a platform, product, or service company. We noticed the performance and correlations of these designations deviate enough that this is an important and interesting risk factor for consideration, and that is the subject of today's research. While we don't agree with every single stock-level categorization, this framework is useful for managing risk in US equities. **Slides 5-7 show the top 25 names in each category by size.**

Key figures: 54% of the companies among the top 2000 equities are services, 39% are products, and 7% are platforms. However, many of the platforms are large, as they account for 21% of the market cap. The largest market cohort is products at 47%. Over time, the platforms cohort has grown at the expense of services. Platforms have steadily gained market share, until recently when product companies advanced, which is sensible given that major Semiconductors are classified as products.

Performance: The platforms have DOMINATED market performance for the last decade. Their industry relative return has been over 40% cumulatively since 2012, vs. industry-relative underperformance for services and products. The cumulative return since 2010 has been over 8x for platforms, 4.8x for products and 3.2x for services. Recently however, **the rolling 6-month**

Adam Parker

Founder
646-734-7070
adam@trivariate.com

performance of the industry-relative returns of the platform category is one of its worst six regimes in the last quarter century.

Relative valuation of platforms has collapsed: After commanding a much higher multiple on price-to-forward earnings for years, the valuation of platforms has consistently compressed since COVID. Among growth stocks, **product companies now trade at a premium on price-to-forward earnings to platforms for the first time since 2012.**

Growth and profitability: The reason for the collapse in the price-to-forward earnings is less about the modest decline in the median platform's forecasted gross margins, but rather about the revenue growth, which while higher in absolute terms, now appears to be decelerating while both products and services topline growth rates are accelerating. Interestingly, the median stock in all three categories has similar net margins today, but platforms are consistently forecasted to have higher net margins since 2024. **That potentially makes estimate achievability for platforms below average.**

Factor efficacy: The market has historically rewarded, not punished, high capital spending-to-sales among platforms. In fact, until the AI revolution began in earnest in 2023, there was little difference in subsequent stock performance by capital intensity quintile. Since 2023, the highest capital-intensity businesses outperformed, peaking early in Q4 last year. Forecasted revenue growth has not been a way to pick winners from losers among products or services companies but was a strong differentiator among platforms from 2019-2020 and again in 2024 and 2025. The platforms with the highest free cash flow yield have cumulatively lagged.

Risk factor: The importance of thinking about these categories comes from their changing behaviors. Products were consistently anti-correlated from services from 2000 through 2021, then became positive correlated post-COVID, and are negatively correlated again. Platforms and products remain slightly anti-correlated, while services have been consistently highly negatively correlated to platforms since COVID. **We see it as sensible to think about exposure to products, services, and platforms as a risk factor relative to the index exposure to these categories.**

Beware of which platforms are positively and negatively correlated to AI Semis (Slide 19), and which stocks trade the most negatively and positively to platforms (Slides 20 and 21) as you assess portfolio level risk. Long / short platform ideas based on recent factor efficacy are shown on Slide 22.

Important Disclosures

Disclaimer

This presentation is confidential and may not be reproduced or distributed without the express prior written permission of Trivariate Research LP and its affiliates (collectively, “**Trivariate**”).

The information contained herein reflects the opinions and projections of Trivariate as the date of publication, which are subject to change without notice at any time subsequent to the date of issue. Trivariate does not represent that any opinion or projection expressed herein will be realized. All information provided is for informational and research purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific portfolio investment, security or other asset. While the information presented herein is believed to be reliable, no representation or warranty is made concerning the accuracy of any data or other information presented. Information obtained by Trivariate from third party sources in connection with the preparation of this presentation has not been independently verified by Trivariate. Additional information regarding Trivariate is available on request.

Any projections, forecasts, targets or other estimates presented herein constitute “forward-looking statements” that can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “forecasted,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” or the negatives thereof or other variations thereon or comparable terminology. Furthermore, any projections, targets, forecasts or other estimates in this presentation are “forward-looking statements” and are based upon certain assumptions that may change. Due to various risks and uncertainties, actual events or results or the actual performance of the funds may differ materially from those reflected or contemplated in such forward-looking statements. Moreover, actual events are difficult to predict and often depend upon factors that are beyond the control of the Trivariate. Nothing herein shall under any circumstances create an implication that the information contained herein is correct as of any time after the earlier of the relevant date specified herein or the date of this presentation. In addition, unless the context otherwise requires, the words “include,” “includes,” “including” and other words of similar import are meant to be illustrative rather than restrictive. Forward-looking statements and discussions of the business environment included herein (e.g., With respect to financial markets, business opportunities, demand, investment pipeline and other conditions) are subject to the ongoing novel coronavirus outbreak (“**COVID**” or “**COVID-19**”). The full impact of COVID-19 is particularly uncertain and difficult to predict, therefore such forward-looking statements do not reflect its ultimate potential.

This shall not constitute an offer to sell or the solicitation of an offer to buy any interests in any fund, product or account that is or may in the future be advised or managed by, Trivariate or any of its affiliates.

All data sourced from S&P Global, Bloomberg, or our Trivariate estimates. All forward-looking-statements reflect the opinion of Trivariate.